Clinical Trials Browser

Pancreatic Neoplasms × rucaparib × Clear all

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04171700 2023-10-02

LODESTAR

Phase 2 Terminated

83 enrolled 16 charts

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03140670 2023-09-28

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Phase 2 Terminated

46 enrolled 16 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02042378 2023-06-13

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Phase 2 Completed

19 enrolled

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

LODESTAR

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation